Medtronic has announced the US launch of Adaptix interbody system, the first navigated titanium implant with Titan nanoLOCK surface technology, a proprietary blend of surface textures on the macro, micro, and nano levels. The announcement was made during the virtual edition of the North American Spine Society (NASS) annual meeting. Adaptix received US Food and Drug Administration (FDA) approval in August 2020.
This represents the first 3D printed titanium implant, developed in-house by Medtronic engineers, that incorporates the state-of-the-art Titan nanoLOCK surface technology.
Titan Spine, acquired in 2019, pioneered this surface technology that is the first to demonstrate the elements to be considered a nanotechnology for spinal devices as outlined in the FDA nanotechnology guidance document. Interbody implants are spacers that surgeons may insert between the vertebrae during spinal fusion surgery to help relieve pressure on nerves and hold the vertebrae in place while fusion occurs.
“Adaptix Interbody System allows me the best chance to meet my patients’ needs by confidently placing the implant under navigation and trusting the Titan nanoLOCK surface technology to allow the implant to promote fusion. Surface technology, material type, and implant design all play a role in bone growth process during fusion,” said J Justin Seale of OrthoArkansas Spine Institute. “The unique features and world-class technologies make the Adaptix Interbody System a truly differentiated implant.”
“Adaptix interbody system is an exciting addition to our portfolio that leads with our Titan nanoLOCK surface technology,” said Sharrolyn Josse, vice president and general manager of Medtronic Core Spine and Biologics division, which is part of the Restorative Therapies Group at Medtronic. “It is a fully navigated procedure, leveraging our leadership in navigation.”